We also find that the S-type lectin LGALS4 has an enrichment of mutations altering the β-galactoside sugar-binding positions in its galectin domains; indeed, LGALS4 has been linked to the regulation of the cancer-relevant Wnt signaling pathway and has been experimentally implicated as a tumor suppressor in colorectal cancer cells in vitro (Satelli et al., 2011). This evidence concerns the gene LGALS4 and cancer.